GET RELIEF IN A MATTER OF WEEKS 

The Medtronic bladder control therapy delivered by the NURO™ system helps you regain bladder control with nerve stimulation. The therapy is administered in your doctor’s office over the course of 12 weeks.

WHAT TO EXPECT

This therapy starts with a series of 12 weekly, 30-minute sessions delivered at your doctor’s office.

  • Use a symptom diary to record any improvements and write down how you’re feeling
  • Remember that most people don’t see any improvement until week 8 or 9 — and for some it takes 12 weeks
  • Finish all 12 weekly sessions before making any decisions with your doctor
  • Continue with maintenance therapy every three to four weeks to sustain your relief

PREVIEW YOUR EXPERIENCE

For a more complete overview of Medtronic bladder control therapy delivered by the NUROTM system, download our comprehensive guidebook.

GET THE GUIDEBOOK
Man and woman enjoying a bike ride outdoors

TRACK YOUR SYMPTOMS

Recording your symptoms can help your doctor understand your condition better.

GET A DIARY

FREQUENTLY ASKED QUESTIONS

Q: WHAT IS MEDTRONIC BLADDER CONTROL THERAPY DELIVERED BY THE NUROTM SYSTEM?

A: This therapy targets the tibial nerve to help you regain control of your bladder.

Q: How does it work?

A: The NUROTM system stimulates the tibial nerve through an acupuncture-like needle placed in the skin near your ankle.

Q: WHY DOES IT TREAT THE TIBIAL NERVE?

A: It’s thought that bladder control problems are caused by miscommunication between the bladder and the central nervous system.1 The tibial nerve connects to nerves responsible for bladder function.

Q: What are the benefits of this therapy?

A: PTNM can be an effective overactive bladder (OAB) treatment that's clinically proven to restore bladder function.2 It doesn't cause side effects like medications can,3 and it doesn’t require self-catheterization.5

Q: WHAT ARE THE POTENTIAL SIDE EFFECTS?

A: The most common side effects are temporary and include mild pain or skin inflammation at or near the stimulation site.

Q: WILL INSURANCE COVER THE COSTS?

A: Medicare and many private insurance companies cover this therapy.

Q: WHAT IS MAINTENANCE THERAPY?

A: Following your initial treatment of 12 weekly, 30-minute sessions, you can continue with maintenance therapy. When you are on maintenance therapy, treatments occur every three to four weeks rather than every week. These sessions are exactly the same as the first 12, and can be scheduled at a time that is convenient for you.

 

POWERFUL CLINICAL EVIDENCE

Decorative image

Evidence shows that Medtronic bladder control therapy by the NURO™ system is an effective treatment for people with OAB.1 Highlights from recent research include the following results:

  • Approximately 90% reduction in the proportion of patients who reported severe or very severe problems with OAB2†
  • Approximately 70% reduction in episodes of incontinence per day after completing the first 12 weekly sessions1
  • Significant improvement in health-related quality of life3,4*
  • Improvements trended as patients completed more sessions and they had the best results when finishing all 124

Are you Ready?

Answer a few quick questions to see if you qualify for treatment.

Take the quiz

TALK TO A BLADDER CONTROL EXPERT

Speak with a doctor in your community who can help you find the right treatment.

FIND A SPECIALIST
*

Evaluated using the Overactive Bladder Symptom Quality of Life Questionnaire (OAB-q)

Evaluated using the Patient Perception of Bladder Condition (PPBC) scale

Restored bladder function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following PTNM treatment.

1

Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin N Am. 2006;33:491-501.

2

Kobashi K, Khandwala S, MacDiarmid S, et al. A Prospective Study to Evaluate Efficacy with the NURO Percutaneous Tibial Neuromodulation System in Drug Naïve Patients with overactive bladder syndrome (OAB). Presented at the American Urological Association 2018 Annual Meeting. Journal of Urology. 2018;199(4) Supplement, Page e987.

3

Peters, K. M., S. A. Macdiarmid, et al. (2009). “Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.” J Urol. 182(3): 1055-1061.

4

Kobashi K, Sand P, Margolis E, et al. Increasing therapy effect over twelve weeks with the NURO™ percutaneous tibial neuromodulation system in drug naïve patients with overactive bladder syndrome (OAB). Presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2019 Winter Meeting. Neurourology and Urodynamics 2019; 38(S1), Page S79.

5

Visco A, Brubaker L, Richter HE et al. Anticholinergic Therapy vs. OnabotulinumtoxinA for Urgency Urinary Incontinence. New Engl J Med. 2012;367(19):1803-1813.

Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.